Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd. ( (AU:RAC) ) has issued an announcement.
Racura Oncology Ltd has applied for quotation of 325,199 new fully paid ordinary shares on the ASX, following the exercise or conversion of existing options or other convertible securities. The issuance modestly expands the company’s share capital base and may provide additional funding flexibility as it advances its oncology-focused activities, though the announcement does not detail specific operational changes or new projects.
The new shares are scheduled to be quoted from April 16, 2026, under the existing RAC ticker, ensuring continuity for investors tracking the stock. This incremental capital move signals ongoing shareholder engagement with Racura Oncology’s equity and could marginally enhance trading liquidity, offering current and prospective investors a slightly broader free float in the company’s securities.
More about Race Oncology Ltd.
Racura Oncology Ltd is an Australian biotechnology company listed on the ASX under the code RAC. The company operates in the oncology sector, focusing on the development of cancer-related therapies or technologies for healthcare and pharmaceutical markets.
Average Trading Volume: 194,456
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$516.2M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.